2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.24 Clinical Prognostic Index for Immunochemiotherapy in Lung Cancer (CLIPI-LC)- A Prognostic Score for Advanced Non-Small-Cell Lung Cancer

EP.11A.24 Clinical Prognostic Index for Immunochemiotherapy in Lung Cancer (CLIPI-LC)- A Prognostic Score for Advanced Non-Small-Cell Lung Cancer

Back to course

Pdf Summary

The document discusses the development and findings of the M. Knetki-Wróblewska Clinical Prognostic Index for Immunochemiotherapy in Lung Cancer (CLIPI-LC), designed to predict outcomes in patients with advanced non-small-cell lung cancer (NSCLC) undergoing immunochemotherapy. The treatment protocol includes pembrolizumab combined with chemotherapy, a standard for advanced NSCLC with high PD-L1 expression, based on the beneficial results from the KEYNOTE-189 and KEYNOTE-407 trials. However, a subset of patients show early progression, necessitating tools for anticipation of this scenario in clinical settings.<br /><br />The study involved a multi-center retrospective analysis of patients treated with pembrolizumab and platinum-based chemotherapy between January 2021 and June 2022. Key inclusion criteria were clinical stage 4 NSCLC, ECOG performance status 0-1, and absence of specific genetic alterations or prior treatments. The prognostic score was devised by evaluating various clinical parameters, considering factors such as weight loss, ECOG status, tumor size, metastatic spread, and specific biomarker levels (e.g., monocytes*NLR).<br /><br />The study included 303 patients with a follow-up period median of 10.52 months. Outcomes demonstrated a median progression-free survival (PFS) of 13.1 months and median overall survival (OS) of 16.3 months. Patients were categorized into prognostic groups: Good, Intermediate, and Poor, with corresponding OS within these groups showing significant differentiation (p<0.001).<br /><br />The results highlighted the varying efficacy of immunochemotherapy in a real-world setting, with CLIPI-LC proving to be a valuable stratification tool based on baseline clinical parameters. Such stratification can guide treatment decisions and improve individualized patient management in advanced NSCLC cases.

Asset Subtitle

Magdalena Knetki-Wróblewska

Meta Tag

Speaker Magdalena Knetki-Wróblewska

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

CLIPI-LC

lung cancer

NSCLC

immunochemotherapy

pembrolizumab

KEYNOTE trials

prognostic index

progression-free survival

overall survival

patient stratification